IMMP Immutep

Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Media Release

SYDNEY, AUSTRALIA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, today announces an abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2023, taking place in San Diego, California and virtually from 1 to 5 November 2023.

Presentation Details

Title: Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab

Abstract Number: 595

Date and Time: Friday, 3 November, 9:00 AM-7:00 PM PT

Location: Exhibit Halls A and B1, San Diego Convention Centre

The abstract will be available on the SITC website as of October 31, 2023, and the poster will be available on the section of Immutep’s website following the presentation.

About SITC

Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumour immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC at .

About Immutep

Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit .

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS

+61 (0)406 759 268;

U.S. Media:

Chris Basta, VP, Investor Relations and Corporate Communications

+1 (631) 318 4000; 



EN
03/10/2023

Underlying

IMMPImmutep

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immutep

 PRESS RELEASE
Free
IMMP IMMUTEP

TACTI-004 Phase III Study in First Line NSCLC to be discontinued follo...

TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), today announced that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa (“efti”) in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility a...

March 13, 2026 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase...

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's targeted enrolment Futility analysis and completion of patient enrolment remain on track for the first quarter and the third quarter of CY2026, respectively SYDNEY, AUSTRALIA, Feb. 06, 2026 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces...

February 6, 2026 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Quarterly Activities Report Q2 FY26

Immutep Quarterly Activities Report Q2 FY26 Media Release Entered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all countries outside North America, Europe, Japan, and Greater ChinaIn January 2026, Immutep received ~A$30 million upfront payment from Dr. Reddy’s and is eligible to receive up to ~A$528 million in potential milestones, plus royalties on commercial sales of eftiStrong operational progress reported for TACTI-004 (KEYNOTE-F91) Phase III trial evaluating efti in first line non-small cell lung cancer (1L NSCLC), with completion o...

January 29, 2026 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Ag...

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levelsDose dependent immunosuppressive effect against a strong foreign antigen observed with continued favourable safety profileSubstantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseasesGiven encouraging efficacy and safety, the trial will continue as planned and further updates are anticipated in 1H CY2026 including present...

December 22, 2025 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Announces Strong Operational Progress in Global TACTI-004 (KEY...

Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial’s targeted enrolmentStrong operational progress continues globally with over 120 activated clinical sites and 27 countries having received full regulatory approvals including the United States Futility analysis remains on track for the first quarter of CY2026 and completion of patient enrolment in the third quarter of CY2026 SYDNEY, AUSTRALIA, Dec. 16, 2025 (GLOBE ...

December 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch